ADCC, produced little pathology. However, unexpectedly, a mutated antibody with ninefold enhanced CDC, but lacking ADCC, produced much less pathology than the original AQP4-Igg. Also, pathology was greatly reduced following administration of AQP4-Igg and complement to mice lacking the FcγIII receptor involved in effector cell activation during ADCC, and to normal mice injected with an Fcγ receptor blocking antibody. Our results provide evidence for the central involvement of ADCC in NMO pathology and suggest ADCC as a new therapeutic target in NMO.
Introduction
Neuromyelitis optica (NMO) is a severe inflammatory demyelinating disease of the central nervous system (CNS) that often produces paralysis and blindness [42] . A defining feature of NMO is the presence of immunoglobulin g autoantibodies in NMO patient serum directed against aquaporin-4 (AQP4) [14, 15] , a water channel present on the plasma membrane of astrocyte end-feet [22, 26] . It is believed that the anti-AQP4 autoantibody (AQP4-Igg) produces astrocyte damage in NMO by a mechanism involving complement-dependent cytotoxicity (CDC), which induces a secondary inflammatory response leading to oligodendrocyte and neuron death [10] . CDC involves multivalent binding of complement protein C1q to the Fc region of AQP4-Igg bound on AQP4 clusters [27] , which leads to formation of a membrane attack complex consisting of complement proteins C5b-C9. The C5 convertase inhibitor eculizumab has demonstrated efficacy in an open-label clinical trial based on the assumed central role of CDC in NMO pathogenesis [28] .
In addition to CDC effector function, which involves C1q binding to the antibody Fc region, AQP4-Igg has ADCC (antibody-dependent cell-mediated cytotoxicity) effector function in which the Fc region binds Fcγ receptors on effector cells and promotes their accumulation, and degranulation. In AQP4-expressing cell cultures, AQP4-Igg can cause cytotoxicity in the presence of natural-killer (NK) cells by an ADCC mechanism [1, 40] . We found that AQP4-Igg and NK-cells can produce NMOlike lesions in mouse brain in the absence of complement, with loss of gFAP and AQP4 but not of myelin [30] . Though human NMO lesions contain few NK-cells [33] , they show an abundance of other leukocyte cell types, including neutrophils, eosinophils and macrophages, each of which express Fcγ receptors and can participate in ADCC [17, 19, 32] . It is unclear whether NMO pathogenesis involves a bona fide ADCC effector mechanism with direct leukocyte interaction with the AQP4-Igg Fc region, or whether the pathogenicity of infiltrating leukocytes is a secondary phenomenon. elucidation of the role of ADCC in NMO pathogenesis is important, as ADCC may be a potential drug target, and therapeutics targeting components late in the complement cascade may have limited efficacy.
Here, we investigated the involvement of ADCC in NMO using engineered monoclonal recombinant AQP4-Igg antibodies with different effector function profiles, including antibodies with enhanced CDC but no ADCC function, and enhanced ADCC but no CDC effector function. The antibodies were generated by mutation of the Fc region of a recombinant monoclonal AQP4-Igg rAb-53, which was derived from a clonally expanded plasma blast recovered from the cerebrospinal fluid of an NMO patient [1] and characterized extensively for its AQP4 binding and pathogenicity [4, 27] . We used a mouse model of NMO involving direct intracerebral injection of AQP4-Igg and complement, which produces human NMO-like pathology with loss of AQP4 and gFAP immunoreactivity, inflammation, perivascular deposition of activated complement and demyelination [34] . We found here, contrary to initial expectations, that ADCC is a major pathogenic mechanism in NMO. ; [21] ), and no CDC or ADCC (l234A/ l235A; Aquaporumab, AQmab; [38] ). Plasmid pcDNA3.1 encoding the M23 isoform of human AQP4 was generated as described [3] .
Materials and methods

Mice
Cell culture and transfections
Chinese hamster ovary (CHO-K1) cells (ATCC CCl-61) were cultured at 37 °C in 5 % CO 2 /95 % air in F12 Ham's medium (Sigma-Aldrich, St. louis, MO, USA) containing 10 % fetal bovine serum (FBS) and 1 % penicillin/streptomycin. CHO-K1 cells stably expressing human AQP4-M23 were generated previously [3] . Human NK-cells and mouse primary astrocytes were cultured as described [30] .
Immunocytochemistry AQP4-expressing cells were incubated for 20 min in blocking buffer (PBS containing 6 mM glucose, 1 mM pyruvate, 1 % bovine serum albumin) and then for 30 min with specified concentrations of AQP4-Igg cont (or mutant antibodies) in blocking buffer. Cells were then rinsed with PBS, fixed in 4 % paraformaldehyde (PFA) for 15 min and permeabilized with 0.1 % Triton X-100. Cells were blocked again and incubated for 30 min with 0.4 μg/ml polyclonal, C-terminal-specific rabbit anti-AQP4 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), then rinsed with PBS. Cells were then incubated for 30 min with 4 μg/ml goat anti-human Igg-conjugated Alexa Fluor 488 and goat anti-rabbit Igg-conjugated Alexa Fluor 555 (Invitrogen, Carlsbad, CA, USA). Quantification of AQP4-Igg binding to AQP4 was performed as described [4] . [(sample − 100 % lysis)/(no lysis − 100 % lysis)] × 100 where '100 % lysis' is fluorescence of cells incubated in 1 % Triton X-100 and 'no lysis' is fluorescence of cells incubated with human complement or NK-cells but no AQP4-Igg.
Intracerebral injection of AQP4-Igg
Intracerebral injection was performed as described [30] . 2 μg AQP4-Igg cont (or mutant antibodies) and 3 μl 20 % human complement in 8 μl PBS (~1 μl/min) were infused into the brain. After 24 h or 3 days, mice were anesthetized and brains were processed for immunostaining. For binding experiments, 2 μg of antibody was injected without complement and mice were killed 24 h later. In some experiments, wild-type mice were administered a rat monoclonal antibody that blocks mouse FcγrII/III (clone 2.4g2, 8 μg/g body weight, BD Biosciences, San Jose, CA, USA) or rat purified Igg (as control) by tail vein 1 h before intracerebral injection of AQP4-Igg cont and human complement. Mice were killed 24 h later, blood was collected by cardiac puncture, leukocytes were counted using a Hemavet 850 (Drew Scientific, Oxford, CT, USA) and brain tissue was processed.
Immunofluorescence and immunohistochemistry
Paraffin sections were immunostained as described [30] using the following antibodies: rabbit anti-AQP4 (1:200, Santa Cruz Biotechnology), mouse anti-gFAP (1:100, Millipore, Temecula, CA, USA), goat anti-myelin basic protein (MBP) (1:200, Santa Cruz Biotechnology), rabbit anti-Iba1 (1:500, Wako, richmond, VA, USA), rat anti-CD45 (1:10, BD Biosciences), mouse anti gr-1 (1:10, eBioscience, Hatfield, UK) or mouse anti-C5b-9 (1:50, Santa Cruz Biotechnology). AQP4, gFAP and MBP immuno-negative areas were defined by hand and quantified blindly by two observers using ImageJ (http://rsbweb.nih.gov/ij/). Data are presented as percentage of immuno-negative area (normalized to total area of hemi-brain slice).
Statistics
Data are presented as mean ± SeM. Statistical comparisons were made using the non-parametric Mann-Whitney test when comparing two groups.
Results
'NMO superantibodies' with enhanced effector functions
To resolve the roles of CDC and ADCC in NMO, point mutations were introduced in the Fc portion of a monoclonal recombinant human AQP4-Igg (rAb-53, referred as AQP4-Igg cont ) that tightly binds to the extracellular surface of both human and mouse AQP4 [1, 4, 29] . The mutations in the CH2 domain of the heavy chain alter the binding affinity of the Fc fragment to C1q or to Fcγ receptors, thereby altering CDC and/or ADCC effector functions, respectively. Figure 1a shows locations of the mutations used to generate the four antibodies used in this study: AQP4-Igg CDC (K326W/e333S), with enhanced CDC and no ADCC; AQP4-Igg ADCC (S239D/A330l/I332e), with enhanced ADCC and no CDC; AQP4-Igg CDC/ADCC (g236A/S267e/H268F/S324T/I332e), with enhanced CDC and ADCC; and AQmab (l234A/l235A) with no CDC or ADCC.
We first verified that mutations introduced in the Fc portion of AQP4-Igg did not alter their binding affinity to AQP4. CHO cells stably expressing human AQP4-M23 were labeled with increasing concentrations of AQP4-Igg (green), and a reference antibody (red) that recognizes the C-terminus of AQP4. Binding was quantified by the green-to-red fluorescence ratio (g/r) as described [4] . It has been shown previously that human Iggs can bind and activate murine effector cells through all classes of Fcγ receptors [25] , as well as induce ADCC mediated by mouse neutrophils, eosinophils and macrophages [25, 44] . In this study, antibody ADCC effector function was assayed in vitro by incubation of AQP4-expressing cells with antibodies and NK-cells, a cell line that has been used extensively in the laboratory previously [30, 38] (Fig. 1d, left) . . These results were confirmed by live/dead cell staining (Fig. 1d, right) . Figure 1e (right) summarizes the dependence of ADCC produced by AQP4-Igg ADCC on NK-cell number.
CDC is required for generation of NMO lesions
To confirm that complement activation is necessary to produce NMO lesions in our model, AQP4-Igg cont and AQP4-Igg ADCC (enhanced ADCC but no CDC function) were injected (separately) with human complement into mouse brains. Three days after injection, mice were killed and brain sections stained for AQP4, gFAP and the myelin marker MBP (Fig. 2a) . As previously reported, injection of AQP4-Igg cont induced astrocyte injury as seen by loss of AQP4 and gFAP staining. AQP4-Igg cont also produced myelin damage as shown by reduced MBP immunoreactivity. Injection of AQP4-Igg cont or human complement alone did not produce pathology (data not shown). Administration of AQP4-Igg ADCC produced very small lesions compared to AQP4-Igg cont as seen in Fig. 2a and by quantification of lesion size (Fig. 2b) . Inflammation, as visualized by CD45 staining, was greatly reduced in mice injected with AQP4-Igg ADCC compared to AQP4-Igg cont . The infiltrating cells were mainly macrophages/microglia as shown by Iba1 staining (Fig. 2c) . We confirmed by C5b-9 immunofluorescence that complement was not activated in mice injected with AQP4-Igg ADCC (Fig. 2c) . These results indicate that the CDC effector function of AQP4-Igg is necessary for generation of NMO lesions.
Similar studies were done with AQP4-Igg CDC/ADCC , which has both CDC and ADCC effector functions enhanced. Figure 2a (Fig. 3a) and by quantification of lesion size (Fig. 3b) . Similar data were obtained in three separate sets of experiments with four mice in each group (Fig. 3c) . Minimal macrophage infiltration was seen in mice injected with AQP4-Igg CDC compared to AQP4-Igg cont (Fig. 3d) . These findings indicate that antibody ADCC effector function worsens lesions produced by AQP4-Igg and complement in mouse brain. Figure 3e shows that differences in antibody binding or diffusion cannot account for the differences in lesion size.
In this single injection model of NMO, macrophages are seen relatively late in the lesions and their role in the development of the pathology is unclear. Neutrophils infiltrate early in the CNS in response to AQP4-Igg and complement [34] . A previous study reported marked neutrophil infiltration at 24 h after AQP4-Igg administration and showed their crucial role in the pathogenesis of the lesions, as neutropenia reduced severity and neutrophilia increased severity [35] . Because neutrophils are known mediators of ADCC, we investigated the effects of AQP4-Igg cont versus AQP4-Igg CDC at 24 h after injection. AQP4-Igg cont causes loss of AQP4 (Fig. 3f) and gFAP, but minimal myelin loss at this early time point. At 24 h, loss of AQP4 was reduced with AQP4-Igg CDC (Fig. 3f, g ). Neutrophil infiltration was greater in AQP4-Igg CDC than with AQP4-Igg cont (Fig. 3h ). These data suggest that the reduced pathology seen with AQP4-Igg CDC is due to reduced ADCC mediated by neutrophils, which are the main inflammatory cells present in the lesion at an early stage.
ADCC in NMO lesions is mediated by Fcγ receptor III
The ADCC data above suggest the involvement of Fcγ receptors in NMO pathogenesis. Murine immune cells express three activating Fcγ receptors: FcγrI, FcγrIII and FcγrIV. The Igg1 response in mice is mainly mediated by FcγrIII [6, 24] . FcγrIII is expressed in macrophages, neutrophils and eosinophils [2] , which are seen abundantly in human NMO lesions and in the NMO intracerebral model in mice [17, 34] . Inactivation of FcγrIII in mice prevents ADCC produced by NK-cells and phagocytosis of Igg1-opsonized cells by macrophages [7] . As AQP4-Igg is an Igg1-subclass antibody, we investigated the role of FcγrIII by intracerebral injection of AQP4-Igg cont and human complement in wild-type and FcγrIII C57Bl/6 knockout mice. Submaximal AQP4-Igg cont was used in this study to generate small (non-saturating) Figure 4a shows significantly reduced pathology in the FcγrIII knockout mice, as confirmed by quantification of lesion size in Fig. 4b . Inflammation was reduced in FcγrIII knockout mice as seen by CD45 and Iba1 staining (Fig. 4c) . ADCC in this NMO model is therefore mediated mainly by FcγrIII.
To explore inhibition of ADCC as a potential new therapeutic option for NMO, we treated mice with a monoclonal antibody that blocks mouse FcγrII and III function by inhibition of Igg binding to the receptors [39] . The FcγrII/III antibody and control Igg were deglycosylated using endoS enzyme, as done previously [37] , to inhibit their effector functions. Antibody was administered intravenously 1 h prior intracerebral injection of AQP4-Igg cont and complement, and the mice were killed 24 h later, at which time blood was collected and the brain harvested. The FcγrII/III antibody reduced by ~30 % the peripheral neutrophil count, with other leukocytes unaffected (Fig. 5a) . Treatment with FcγrII/III antibody significantly reduced lesion size in brain as seen by AQP4 and gFAP immunoreactivity (Fig. 5b, c) . Inflammation in the treated mice was comparable to control mice (Fig. 5d) . We confirmed the binding of the FcγrII/III antibody to neutrophils in the treated mice by staining with a fluorescent secondary antibody (Fig. 5d) .
Discussion
We used engineered monoclonal AQP4-Iggs to investigate the importance of antibody CDC versus ADCC effector functions in the generation of NMO lesions in mice. Addition of complement in the absence of effector leukocytes can produce CDC efficiently in various in vitro AQP4-transfected target cells and ex vivo spinal cord explants [27, 43] . We found here that AQP4-Igg lacking ADCC effector function, even with enhanced CDC effector function, produced reduced NMO pathology in vivo. Together with data showing reduced pathology in FcγIII receptor knockout mice and mice treated with a Fcγ receptor blocking antibody, we conclude that ADCC plays a central pathogenic role in NMO lesions produced by AQP4-Igg. We also confirmed CDC as a primary pathogenic process in NMO, as seen by the absence of NMO lesions with an AQP4-Igg lacking CDC effector function, but with enhanced ADCC effector function. Though a limited number of mice were used in the studies here, the findings were robust and clear-cut.
NMO lesion pathology and experimental models have suggested a key role for granulocytes and macrophages in NMO pathogenesis [9] . Neutrophils, eosinophils and macrophages are prominently seen in human NMO lesions [17, 19, 32] . Studies using the mouse intracerebral injection model show reduced lesion size in mice made neutropenic or hypoeosinophilic, and increased lesion size in mice made neutrophilic or hypereosinophilic [35, 44] . Also, addition of purified neutrophil elastase or eosinophil granule toxins worsened astrocyte loss and demyelination in an ex vivo spinal cord slice culture model of NMO. Finally, the neutrophil elastase inhibitor sivelestat and the secondgeneration antihistamine cetirizine (which has eosinophil stabilizing actions) reduced NMO pathology in in vivo and ex vivo mouse models [35, 44] , suggesting the potential utility of neutrophil-and eosinophil-targeted therapies in NMO. The addition of macrophages to spinal cord cultures also exacerbated AQP4-Igg tissue injury [43] , though their role in CNS injury in vivo has not been studied.
Mice express three different activating Fcγ receptors: neutrophils and eosinophils express FcγrIII and FcγrIV, and macrophages express FcγrI, FcγrIII and FcγrIV [41] . Binding of Fcγ receptors to the Fc portion of Igg mediates effector cell activation and promotes ADCC, resulting in effector cell degranulation and target cell lysis or phagocytosis. Since AQP4-Igg lacking ADCC effector function has decreased affinity for Fcγ receptors in general, the reduced pathology could also be partly due to reduced phagocytic activity from infiltrating cells. We found an important role of FcγrIII in AQP4-Igg-mediated ADCC in the intracerebral injection model of NMO. FcγrIII deficient mice showed little cell infiltration and astrocyte damage when administered AQP4-Igg and human complement. Previous data from FcγrIII −/− mice have demonstrated that FcγrIII triggers Arthus reaction and passive cutaneous anaphylaxis [7] , Igg1-induced passive systemic anaphylaxis [20] and collagen-induced arthritis [5] . A major role of FcγrIII in NMO lesion formation is consistent with observations that FcγrI is expressed mainly on macrophages and not in neutrophils or eosinophils, which are the immune cells present early in NMO lesions [35] and probably the major mediators of astrocyte damage, as well as the observation that FcγrIV binds mainly mouse Igg2a and Igg2b [23] . Administration of an FcγrII/III blocking antibody reduced pathology, probably by a combination of direct ADCC inhibition and reduced peripheral neutrophil count.
Our findings have implications for new NMO therapeutics. As ADCC aggravates NMO pathology, therapeutics targeting ADCC are predicted to have potential benefit in NMO when used alone or together with therapies targeting CDC, AQP4-Igg binding to CNS astrocytes, or neutrophil/eosinophil degranulation. However, translation of our findings concerning the specific role of FcγrIII in NMO lesions to the human pathology are limited by dissimilarities in the binding specificity and expression pattern of human versus murine Fcγ receptors. For example, in humans FcγrIIIA is not expressed in neutrophils, but only in NK-cells and macrophages [2] . Identification of the Fcγ receptors involved in human NMO pathology is therefore required before development of therapeutics targeting ADCC in NMO.
The data presented here suggest an interplay between CDC and ADCC in the development of NMO pathology. CDC is the principal mechanism causing pathology in many diseases such as paroxysmal nocturnal hemoglobinuria, hereditary angioedema, age-related macular degeneration and atypical hemolytic-uremic syndrome [31] . ADCC is the principal effector mechanism employed by antibodies in tumor surveillance and viral clearance. Polymorphisms in Fcγrs that affect their binding to Iggs have been associated with altered clinical efficacy of rituximab, an anti-CD20 monoclonal antibody used in the treatment of B cell lymphomas [41] . It was shown previously that both complement and Fcγrs are necessary for pathology in several autoimmune diseases, including rheumatoid arthritis, anti-gBM glomerulonephritis and blistering diseases [18] . Our data support the addition of NMO to this list. Figure 6 shows a proposed mechanism for AQP4-Igg pathogenesis based on our data. AQP4-Igg enters the CNS, by an unknown mechanism, and binds AQP4 on astrocyte end-feet. This is followed by C1q binding and activation of the complement cascade. Cleavage of complement proteins C3 and C5 produces anaphylatoxins C3a and C5a, which are potent chemoattractants of neutrophils, eosinophils, and monocytes into the CNS [11] . It has been shown that anaphylatoxins participate in CNS inflammation in several neurodegenerative diseases and increase microvascular permeability, which may augment the CNS entry of AQP4-Igg. Importantly, binding of C5a to its receptor on inflammatory cells increases expression of activating Fcγrs [36] . Thus, C5a has a dual role in the cross-talk between CDC and ADCC: recruitment of inflammatory cells toward sites of complement activation and enhancement of ADCC mediated by these cells.
The involvement of C5a in NMO is supported by a recent study showing elevation of C5a levels in the cerebrospinal fluid of NMO patients [12] . Inflammatory cells that enter the CNS bind the Fc portion of AQP4-Igg through Fcγrs, which leads to their degranulation. Secondary oligodendrocyte death, demyelination and neuronal injury may result from the direct effects of activated complement products, such as anaphylatoxins and toxic granules, or indirectly through astrocyte injury. engineered monoclonal AQP4-Iggs with altered effector function profiles offer unique opportunities to understand NMO pathogenesis and develop novel therapies. A variety of approaches to modulate Igg effector functions have been developed, involving mutagenesis of the Igg Fc region or alteration in Igg glycosylation [16] . We previously introduced the concept of aquaporumab anti-AQP4 antibodies as a therapeutic strategy in NMO [38] . As a nonpathogenic, high-affinity antibody lacking CDC and ADCC effector functions, aquaporumab competes with pathogenic AQP4-Igg for binding to AQP4, preventing downstream astrocyte cytotoxicity, inflammatory cell recruitment and demyelination. An alternative strategy involving enzymatic deglycosylation of AQP4-Igg was also developed [37] . In addition to the application here to resolve CDC versus ADCC effector functions, AQP4-Iggs with enhanced effectors functions, or 'NMO superantibodies', may be useful in creating more robust animal models of NMO than are currently available, such as passive-transfer models based on peripheral AQP4-Igg administration. In conclusion, our results indicate the central involvement of both CDC and ADCC in NMO pathogenesis. As such, therapies targeting ADCC are predicted to be effective in NMO.
